163 related articles for article (PubMed ID: 23076703)
41. Psychophysical measurement of rod and cone thresholds in stargardt disease with full-field stimuli.
Collison FT; Fishman GA; McAnany JJ; Zernant J; Allikmets R
Retina; 2014 Sep; 34(9):1888-95. PubMed ID: 24695063
[TBL] [Abstract][Full Text] [Related]
42. [Dobesilate Calcium in the treatment of chronic kidney failure].
Liu XC; Lu YM; Jin XB; Zeng HB; Gao HY
Zhonghua Yi Xue Za Zhi; 2004 Nov; 84(22):1892-3. PubMed ID: 15631801
[No Abstract] [Full Text] [Related]
43. Progression of Stargardt Disease as Determined by Fundus Autofluorescence in the Retrospective Progression of Stargardt Disease Study (ProgStar Report No. 9).
Strauss RW; Muñoz B; Ho A; Jha A; Michaelides M; Cideciyan AV; Audo I; Birch DG; Hariri AH; Nittala MG; Sadda S; West S; Scholl HPN;
JAMA Ophthalmol; 2017 Nov; 135(11):1232-1241. PubMed ID: 29049437
[TBL] [Abstract][Full Text] [Related]
44. Abnormality in the external limiting membrane in early Stargardt disease.
Burke TR; Yzer S; Zernant J; Smith RT; Tsang SH; Allikmets R
Ophthalmic Genet; 2013; 34(1-2):75-7. PubMed ID: 22871184
[TBL] [Abstract][Full Text] [Related]
45. Complement modulation in the retinal pigment epithelium rescues photoreceptor degeneration in a mouse model of Stargardt disease.
Lenis TL; Sarfare S; Jiang Z; Lloyd MB; Bok D; Radu RA
Proc Natl Acad Sci U S A; 2017 Apr; 114(15):3987-3992. PubMed ID: 28348233
[TBL] [Abstract][Full Text] [Related]
46. Macular function and morphologic features in juvenile stargardt disease: longitudinal study.
Testa F; Melillo P; Di Iorio V; Orrico A; Attanasio M; Rossi S; Simonelli F
Ophthalmology; 2014 Dec; 121(12):2399-405. PubMed ID: 25097154
[TBL] [Abstract][Full Text] [Related]
47. Peripheral Pigmented Retinal Lesions in Stargardt Disease.
Zhao PY; Abalem MF; Nadelman D; Qian CX; Branham K; Schlegel D; Khan N; Heckenlively JR; Jayasundera T
Am J Ophthalmol; 2018 Apr; 188():104-110. PubMed ID: 29288030
[TBL] [Abstract][Full Text] [Related]
48. Multimodal analysis of the Preferred Retinal Location and the Transition Zone in patients with Stargardt Disease.
Verdina T; Greenstein VC; Sodi A; Tsang SH; Burke TR; Passerini I; Allikmets R; Virgili G; Cavallini GM; Rizzo S
Graefes Arch Clin Exp Ophthalmol; 2017 Jul; 255(7):1307-1317. PubMed ID: 28365912
[TBL] [Abstract][Full Text] [Related]
49. Bicyclic [3.3.0]-Octahydrocyclopenta[c]pyrrolo Antagonists of Retinol Binding Protein 4: Potential Treatment of Atrophic Age-Related Macular Degeneration and Stargardt Disease.
Cioffi CL; Racz B; Freeman EE; Conlon MP; Chen P; Stafford DG; Schwarz DM; Zhu L; Kitchen DB; Barnes KD; Dobri N; Michelotti E; Cywin CL; Martin WH; Pearson PG; Johnson G; Petrukhin K
J Med Chem; 2015 Aug; 58(15):5863-88. PubMed ID: 26181715
[TBL] [Abstract][Full Text] [Related]
50. Identification of the PROM1 Mutation p.R373C in a Korean Patient With Autosomal Dominant Stargardt-like Macular Dystrophy.
Kim JM; Lee C; Lee GI; Kim NKD; Ki CS; Park WY; Kim BJ; Kim SJ
Ann Lab Med; 2017 Nov; 37(6):536-539. PubMed ID: 28840994
[TBL] [Abstract][Full Text] [Related]
51. Stargardt disease caused by a rare combination of double homozygous mutations.
Serapinas D; Obrikytė V; Sakalauskas R
Medicina (Kaunas); 2013; 49(8):386-91. PubMed ID: 24509150
[TBL] [Abstract][Full Text] [Related]
52. Infrared scanning laser ophthalmoscope imaging of the macula and its correlation with functional loss and structural changes in patients with stargardt disease.
Anastasakis A; Fishman GA; Lindeman M; Genead MA; Zhou W
Retina; 2011 May; 31(5):949-58. PubMed ID: 21293320
[TBL] [Abstract][Full Text] [Related]
53. Rescue of the Stargardt phenotype in Abca4 knockout mice through inhibition of vitamin A dimerization.
Charbel Issa P; Barnard AR; Herrmann P; Washington I; MacLaren RE
Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8415-20. PubMed ID: 26106163
[TBL] [Abstract][Full Text] [Related]
54. Fluorescence Lifetime Imaging in Stargardt Disease: Potential Marker for Disease Progression.
Dysli C; Wolf S; Hatz K; Zinkernagel MS
Invest Ophthalmol Vis Sci; 2016 Mar; 57(3):832-41. PubMed ID: 26934141
[TBL] [Abstract][Full Text] [Related]
55. Prevention of diabetic retinopathy.
Einarsdóttir AB; Stefánsson E
Lancet; 2009 Apr; 373(9672):1316-8. PubMed ID: 19376433
[No Abstract] [Full Text] [Related]
56. Experimental studies on medical treatments of retinal dystrophies with a particular focus on ABCA4 retinopathies.
Sciezynska A; Ozieblo D; Oldak M
Klin Oczna; 2016 Aug; 118(1):59-65. PubMed ID: 29715411
[TBL] [Abstract][Full Text] [Related]
57. RETINAL FLECKS IN STARGARDT DISEASE REVEAL CHARACTERISTIC FLUORESCENCE LIFETIME TRANSITION OVER TIME.
Solberg Y; Dysli C; Escher P; Berger L; Wolf S; Zinkernagel MS
Retina; 2019 May; 39(5):879-888. PubMed ID: 30985551
[TBL] [Abstract][Full Text] [Related]
58. Differential Disease Progression in Atrophic Age-Related Macular Degeneration and Late-Onset Stargardt Disease.
Lindner M; Lambertus S; Mauschitz MM; Bax NM; Kersten E; Lüning A; Nadal J; Schmitz-Valckenberg S; Schmid M; Holz FG; Hoyng CB; Fleckenstein M;
Invest Ophthalmol Vis Sci; 2017 Feb; 58(2):1001-1007. PubMed ID: 28288486
[TBL] [Abstract][Full Text] [Related]
59. Visual Cortex Activation in Patients With Stargardt Disease.
Melillo P; Prinster A; Di Iorio V; Olivo G; D'Alterio FM; Cocozza S; Orrico A; Quarantelli M; Testa F; Brunetti A; Simonelli F
Invest Ophthalmol Vis Sci; 2018 Mar; 59(3):1503-1511. PubMed ID: 29625472
[TBL] [Abstract][Full Text] [Related]
60. Disruption in Bruch membrane in patients with Stargardt disease.
Park SP; Chang S; Allikmets R; Smith RT; Burke TR; Gregory-Roberts E; Tsang SH
Ophthalmic Genet; 2012 Mar; 33(1):49-52. PubMed ID: 22060670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
